Physician profile
Gary Lee Oxenberg
NPI 1346214533
$1,404.71
in general payments reported to CMS, 2019-2025
23 companies · $494 in 2025
The $494 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $41.58 · 2021: $181 · 2022: $43.40 · 2023: $28.83 · 2024: $476 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $317.08 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Sunovion Pharmaceuticals INC. | $140.72 | 2019 | |
| Novo Nordisk INC | $116.01 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $112.42 | 2021 | |
| Axsome Therapeutics, INC. | $103.19 | 2024-2025 | Auvelity |
| Pfizer INC. | $87.15 | 2024-2025 | |
| Corcept Therapeutics | $64.40 | 2024-2025 | Korlym |
| Lilly USA, LLC | $60.69 | 2020-2024 | Mounjaro, Zepbound |
| Amgen INC. | $60.26 | 2024-2025 | Repatha, Otezla, Repatha |
| Medtronic, INC. | $53.38 | 2021 | |
| Abbvie INC. | $48.06 | 2022-2024 | |
| Sequel Med Tech, LLC | $28.40 | 2025 | Twiist |
| Daiichi Sankyo INC. | $27.14 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $24.17 | 2024 | Rexulti |
| Azurity Pharmaceuticals, INC. | $23.61 | 2024 | Horizant |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.32 | 2025 | |
| Radius Health, INC. | $20.07 | 2025 | |
| Lundbeck LLC | $19.09 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $17.88 | 2025 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $16.31 | 2025 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $14.80 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.73 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.83 | 2023 | Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Oxenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.